Precigen, Inc. (NASDAQ:PGEN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Precigen, Inc. (NASDAQ:PGEN) have been assigned an average recommendation of “Moderate Buy” from the five research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $6.33.

Several equities analysts recently issued reports on PGEN shares. JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of Precigen in a research note on Tuesday, January 14th. HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Precigen in a research note on Friday, November 15th.

Institutional Investors Weigh In On Precigen

A number of hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC raised its position in Precigen by 27.9% in the 4th quarter. SG Americas Securities LLC now owns 57,641 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 12,578 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of Precigen by 10.2% in the 3rd quarter. Exchange Traded Concepts LLC now owns 167,496 shares of the biotechnology company’s stock valued at $159,000 after acquiring an additional 15,525 shares during the last quarter. Stifel Financial Corp increased its holdings in shares of Precigen by 94.9% in the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 15,680 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Precigen by 40.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 16,486 shares during the last quarter. Finally, AQR Capital Management LLC increased its holdings in shares of Precigen by 56.7% in the 2nd quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock valued at $79,000 after acquiring an additional 18,097 shares during the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen Stock Performance

PGEN opened at $1.11 on Monday. The stock’s 50-day moving average price is $0.91 and its 200 day moving average price is $1.06. Precigen has a 12-month low of $0.65 and a 12-month high of $1.93. The firm has a market cap of $325.08 million, a price-to-earnings ratio of -2.02 and a beta of 1.65.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.